Overview Psoriatic Arthritis Study of Izokibep Status: Recruiting Trial end date: 2024-12-01 Target enrollment: Participant gender: Summary Izokibep is a potent and selective inhibitor of interleukin (IL)-17A that is being developed for treatment of psoriatic arthritis (PsA). This study will evaluate the efficacy of izokibep in subjects with PsA. Phase: Phase 2/Phase 3 Details Lead Sponsor: ACELYRIN Inc.